Expect near-term selling pressure from the 10.8% share count increase and the overhang of potential future dilution from outstanding options (7.1M), pre-funded warrants (7.7M), and convertible debt (Wellcome and K2). Monitor whether the ALTO-207 Phase 3 catalyst can offset dilution over a weeks-to-months horizon. The $93.9M raise extends cash runway through 2030 per management, but pricing at market (no discount) suggests institutional demand without a panic discount—watch for any subsequent equity-linked draws.
Price Chart
Executive Summary
Alto Neuroscience is conducting a $100M underwritten public offering of 3,776,436 shares at $26.48 per share (at-the-market), with $93.9M net proceeds to fund accelerated Phase 3 development of ALTO-207 for treatment-resistant depression and general working capital. The offering was priced on July 13, 2026, one day after a preliminary cash balance disclosure of ~$244.2M and pipeline expansion plans, signaling a near-term capital need despite strong analyst consensus. Immediate dilution to new investors is $17.80 per share (67% of offering price), and the increased share count (10.8% pro forma) will pressure the stock near-term.
Key Facts
- Offering of 3,776,436 shares at $26.48/share (last sale price on July 10, 2026), total gross proceeds of $100,000,025.28
- Net proceeds ~$93.9M after underwriting discounts of $5.5M and estimated expenses of $650K
- Pro forma shares outstanding of 38,829,167, up from 35,052,731 (10.8% increase)
- Use of proceeds: accelerate and expand ALTO-207 clinical development, including additional Phase 3 monotherapy trial for treatment-resistant depression
- Preliminary cash balance of ~$244.2M as of June 30, 2026 (unaudited), down from $264.2M at Q1 end
- Immediate dilution of $17.80 per share to new investors (offering price of $26.48 minus as-adjusted net tangible book value of $8.68)
- 60-day lock-up on shares held by executive officers and directors
- Underwriters: BofA Securities (lead), Stifel, William Blair, Baird, JonesTrading, H.C. Wainwright
Financial Impact
Net proceeds of $93.9M, representing ~9.5% of pre-offering market cap of $984M. Dilution of $17.80 per share (67% of offering price). Pro forma market cap ~$1.03B.
Risk Factors
- Immediate 10.8% dilution from new shares with potential for further dilution from outstanding options, warrants, and convertible instruments
- Clinical-stage biotech with no approved products or revenue—trial failure or regulatory setback could sharply impact valuation despite extended cash runway
- 67% dilution-to-offering-price ratio signals significant value transfer from existing to new investors
- Lock-up expiration after 60 days could add secondary selling pressure from insiders and pre-offering holders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-083268 |
| Document: 0001104659-26-083268-index-headers.html | 0001104659-26-083268 |
| Document: 0001104659-26-083268-index.html | 0001104659-26-083268 |
| Document: 0001104659-26-083268.txt | 0001104659-26-083268 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | Institutional Cluster | $32.30 $34.25 | ▲ +6.04% | ▲ +8.00% | $23.18 (−28.24%) |
Jul 14, 2026 15w ago | 8-K | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $23.18 (+16.62%) |
Jul 14, 2026 15w ago | 424B5 | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $23.18 (+16.62%) |
Jul 13, 2026 15w ago | 8-K | $28.03 $27.54 | ▼ −1.75% | ▼ −0.96% | $23.18 (−17.30%) |
Jun 11, 2026 19w ago | Institutional Cluster | $21.47 $22.74 | ▲ +5.92% | ▲ +5.24% | $23.18 (+7.96%) |
May 29, 2026 21w ago | 3 | $19.80 $18.26 | ▼ −7.78% | ▼ −5.03% | $23.18 (+17.07%) |
May 28, 2026 21w ago | 8-K | $20.22 $18.85 | ▼ −6.78% | ▼ −6.73% | $23.18 (+14.64%) |
May 13, 2026 23w ago | 8-K | $22.85 $20.45 | ▼ −10.50% | ▼ −9.35% | $23.18 (+1.44%) |
Apr 21, 2026 27w ago | EFFECT | $25.59 $24.47 | ▼ −4.38% | ▼ −5.46% | $23.18 (−9.42%) |
Apr 10, 2026 28w ago | S-3 | $25.75 $27.33 | ▲ +6.14% | ▲ +2.84% | $23.18 (−9.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers